+

WO2011063164A3 - Sustained release cannabinoid medicaments - Google Patents

Sustained release cannabinoid medicaments Download PDF

Info

Publication number
WO2011063164A3
WO2011063164A3 PCT/US2010/057302 US2010057302W WO2011063164A3 WO 2011063164 A3 WO2011063164 A3 WO 2011063164A3 US 2010057302 W US2010057302 W US 2010057302W WO 2011063164 A3 WO2011063164 A3 WO 2011063164A3
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoid
therapeutic
present
medicaments
sustained release
Prior art date
Application number
PCT/US2010/057302
Other languages
French (fr)
Other versions
WO2011063164A2 (en
Inventor
David Carley
Peter Letendre
Kenton Fedde
John Koleng
Original Assignee
Steady Sleep Rx Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steady Sleep Rx Co., Inc. filed Critical Steady Sleep Rx Co., Inc.
Publication of WO2011063164A2 publication Critical patent/WO2011063164A2/en
Publication of WO2011063164A3 publication Critical patent/WO2011063164A3/en
Priority to US13/474,666 priority Critical patent/US20120231083A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a medicament which results in delivery of a therapeutic level of one or more cannabinoids during a clinically relevant therapeutic window. The therapeutic window is a longer window than provided by an immediate release medicament such as Marinol containing an equivalent amount of the cannabinoid. Oral administration of the present compositions provides therapeutic dosing while maintaining safe, side effect sparing, levels of a cannabinoid. The present invention also provides methods of treating cannabinoid-sensitive disorders.
PCT/US2010/057302 2009-11-18 2010-11-18 Sustained release cannabinoid medicaments WO2011063164A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/474,666 US20120231083A1 (en) 2010-11-18 2012-05-17 Sustained release cannabinoid medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26252309P 2009-11-18 2009-11-18
US61/262,523 2009-11-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/474,666 Continuation US20120231083A1 (en) 2010-11-18 2012-05-17 Sustained release cannabinoid medicaments

Publications (2)

Publication Number Publication Date
WO2011063164A2 WO2011063164A2 (en) 2011-05-26
WO2011063164A3 true WO2011063164A3 (en) 2011-10-06

Family

ID=44060346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/057302 WO2011063164A2 (en) 2009-11-18 2010-11-18 Sustained release cannabinoid medicaments

Country Status (1)

Country Link
WO (1) WO2011063164A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013012468A2 (en) * 2010-11-18 2016-09-06 Pier Pharmaceuticals method of treating an individual with a cannabinoid-sensitive disorder, establishing an optimal dose, treating an individual with a sleep apnea disorder, and
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
WO2013018050A2 (en) * 2011-08-01 2013-02-07 Ranbaxy Laboratories Limited Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
WO2013147965A1 (en) * 2012-03-28 2013-10-03 Freeman Keith Gerald Medical compositions, methods of making and using those compositions, and kits including those compositions
CN103202811B (en) * 2013-03-22 2015-04-15 中山大学 Diflunisal solid dispersion and preparation method thereof
WO2015025312A1 (en) * 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
MX2016006657A (en) 2013-11-22 2016-10-12 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis.
EP3171871B1 (en) * 2014-07-21 2024-10-23 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
MX2017003561A (en) * 2014-08-22 2017-08-28 Medipath Inc Compositions and methods for cannabinoid coatings for use in drug delivery.
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016160542A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CN105168163A (en) * 2015-09-23 2015-12-23 中国药科大学 Indissolvable drug oral sustained-release dry emulsion tablet and preparation method thereof
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
US11701323B2 (en) 2016-06-28 2023-07-18 Trichomeshell Ltd. Dosage form for vaporization and smoking
US10772837B2 (en) * 2017-03-16 2020-09-15 CannTab Therapeutics, Ltd Modified release multi-layer tablet cannabinoid formulations
US11612581B2 (en) 2017-08-09 2023-03-28 Cannibite Bvba Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects
IL273904B2 (en) * 2017-10-09 2024-08-01 Rhodes Pharmaceuticals Lp Medicinal resin components and methods for their production and use
EP3746068A4 (en) * 2018-01-29 2021-11-03 Evero Compositions and methods for treating obstructive sleep apnea
WO2019180505A1 (en) * 2018-03-19 2019-09-26 Emerald Health Therapeutics Canada Inc. Defined dose cannabis pod
CN112739328B (en) * 2018-07-18 2024-03-08 戈拉特有限责任公司 Quick release formulation of cannabinoids
US20210015743A1 (en) * 2019-07-16 2021-01-21 Yoseph Seyoum Treatment of irritable bowel and inflammatory bowel disease
WO2021151169A1 (en) * 2020-01-31 2021-08-05 AusCann Group Holdings Ltd Cannabinoid composition and manufacturing method
WO2021151168A1 (en) * 2020-01-31 2021-08-05 AusCann Group Holdings Ltd Method of cannabinoid therapy
CA3198142A1 (en) 2021-01-29 2022-08-04 Edward M. Rudnic Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders
US20230338399A1 (en) * 2022-04-22 2023-10-26 Curio Ip, Llc Oral cannabinoid pharmaceutical compositions and methods of treating inflammatory gastrointestinal disorders
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127572A1 (en) * 2001-04-06 2004-07-01 Carley David W. Functional role for cannabinoids in autonomic stability during sleep
US20070232528A1 (en) * 2004-04-30 2007-10-04 Hanshermann Franke Formulation comprising histone deacetylase inhibitors
WO2008070268A2 (en) * 2006-10-09 2008-06-12 Charleston Laboratories, Inc. Pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127572A1 (en) * 2001-04-06 2004-07-01 Carley David W. Functional role for cannabinoids in autonomic stability during sleep
US20070232528A1 (en) * 2004-04-30 2007-10-04 Hanshermann Franke Formulation comprising histone deacetylase inhibitors
WO2008070268A2 (en) * 2006-10-09 2008-06-12 Charleston Laboratories, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
WO2011063164A2 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
WO2011063164A3 (en) Sustained release cannabinoid medicaments
WO2012068516A3 (en) Low dose cannabinoid medicaments
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
WO2006044421A3 (en) Cardiac safe, rapid medication delivery
WO2009102893A3 (en) Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors
MX369385B (en) Products for healing of tissue wounds.
BR112014008789A2 (en) prevention and treatment of eye conditions
WO2014022739A3 (en) Modified rnai agents
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
UY34358A (en) ? TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND ACETATO DE GLATIRAMER ?.
MY166014A (en) Combination therapy methods for treating proliferative diseases
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.
WO2008011173A3 (en) Improvement of arginase levels/activity
ECSP099556A (en) NEW METHODS
WO2010085820A3 (en) Tricyclic compounds as antagonists of prostaglandin d2 receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10832214

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22-08-2012.)

122 Ep: pct application non-entry in european phase

Ref document number: 10832214

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载